Search

Your search keyword '"Tjin-A-Ton, Manuel L. R."' showing total 12 results
Start Over Author "Tjin-A-Ton, Manuel L. R."
12 results on '"Tjin-A-Ton, Manuel L. R."'

1. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Author

Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, On Behalf Of The Plcrc Study Group, Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, and On Behalf Of The Plcrc Study Group

Published
2022

2. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care

Author

Derksen, Jeroen W. G., Vink, Geraldine R., Elferink, Marloes A. G., Roodhart, Jeanine M. L., Verkooijen, Helena M., van Grevenstein, Wilhelmina M. U., Siersema, Peter D., May, Anne M., Koopman, Miriam, Beets, Geerard L., Belt, Eric J. Th., Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L. O., van Cruijsen, Hester, Dekker, Jan Willem T., van Dodewaard-de Jong, Joyce M., Erdkamp, Frans L. G., de Groot, Jan Willem B., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., de Hingh, Ignace H. J. T., Hoekstra, Ronald, Ijzermans, Jan N. M., Jansen, Jan, Kloppenberg, Frank W. H., van Lent, Anja U. G., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J. M., Nieboer, Peter, Peeters, Koen C. M. J., Peters, Natascha A. J. B., Polée, Marco B., Pruijt, Johannes F. M., Punt, Cornelis J. A., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H. W., van der Velden, Arjan Schouten, Schrauwen, Ruud W. M., Sie, Mark P. S., Simkens, Lieke, Sommeijer, Dirkje W., Sonneveld, Dirk J. A., Spierings, Leontine E. A., Stockmann, Hein B. A. C., Talsma, Koen, Terheggen, Frederiek, ten Tije, Albert J., Tjin-A-Ton, Manuel L. R., Valkenburg-van Iersel, Liselot B. J., Veenstra, Renzo P., van der Velden, Ankie M. T., Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F. J., van Voorthuizen, Theo, de Vos, Aad I., Wegdam, Johannes A., de Wilt, Johannes H. W., Zimmerman, David D. E., Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Epidemiologie, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, Internal medicine, and VU University medical center

Subjects
Male, medicine.medical_specialty, Colorectal cancer, Epidemiology, Science, Population, MODELS, MEDLINE, Logistic regression, Representativeness heuristic, Article, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Cancer epidemiology, Medical research, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Multidisciplinary approach, COLON, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Registries, education, Aged, Netherlands, Aged, 80 and over, education.field_of_study, Multidisciplinary, business.industry, Middle Aged, medicine.disease, Cancer registry, TRIALS, Outcomes research, 030220 oncology & carcinogenesis, Family medicine, Cohort, Medicine, Female, business, Colorectal Neoplasms
Abstract

Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the “real-world”. Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013–2016 and 2017–Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64–0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017–Aug’19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC’s representativeness and its contribution to a learning healthcare system.

Published
2021
Full Text
View/download PDF

3. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

Author

Verpleegafdeling Medische Oncologie, Onderzoek Medische Oncologie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Wensink, G Emerens, Elferink, Marloes A G, May, Anne M, Mol, Linda, Hamers, Patricia A H, Bakker, Sandra D, Creemers, Geert-Jan, de Groot, Jan Willem B, de Klerk, Gerty J, Haberkorn, Brigitte C M, Haringhuizen, Annebeth W, Hoekstra, Ronald, Hunting, J Cornelis B, Kerver, Emile D, Mathijssen-van Stein, Danielle, Polée, Marco B, Pruijt, Johannes F M, Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C, Simkens, Lieke H J, Tanis, Bea C, Ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L R, Tromp-van Driel, Cathrien S, Troost, Monique M, van de Wouw, Agnes J, van den Berkmortel, Franchette W P J, van der Pas, Anke J M, van der Velden, Ankie M T, van Dijk, Marjan A, van Dodewaard-de Jong, Joyce M, van Druten, Edith B, van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M W, Vestjens, Hanneke J H M J, Vincent, Jeroen, Kranenburg, Onno W, Punt, Cornelis J A, Vink, Geraldine R, Roodhart, Jeanine M L, Koopman, Miriam, Verpleegafdeling Medische Oncologie, Onderzoek Medische Oncologie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Wensink, G Emerens, Elferink, Marloes A G, May, Anne M, Mol, Linda, Hamers, Patricia A H, Bakker, Sandra D, Creemers, Geert-Jan, de Groot, Jan Willem B, de Klerk, Gerty J, Haberkorn, Brigitte C M, Haringhuizen, Annebeth W, Hoekstra, Ronald, Hunting, J Cornelis B, Kerver, Emile D, Mathijssen-van Stein, Danielle, Polée, Marco B, Pruijt, Johannes F M, Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C, Simkens, Lieke H J, Tanis, Bea C, Ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L R, Tromp-van Driel, Cathrien S, Troost, Monique M, van de Wouw, Agnes J, van den Berkmortel, Franchette W P J, van der Pas, Anke J M, van der Velden, Ankie M T, van Dijk, Marjan A, van Dodewaard-de Jong, Joyce M, van Druten, Edith B, van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M W, Vestjens, Hanneke J H M J, Vincent, Jeroen, Kranenburg, Onno W, Punt, Cornelis J A, Vink, Geraldine R, Roodhart, Jeanine M L, and Koopman, Miriam

Published
2021

4. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer : Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

5. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

6. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

Author

Wensink, G. Emerens, primary, Elferink, Marloes A. G., additional, May, Anne M., additional, Mol, Linda, additional, Hamers, Patricia A. H., additional, Bakker, Sandra D., additional, Creemers, Geert-Jan, additional, de Groot, Jan Willem B., additional, de Klerk, Gerty J., additional, Haberkorn, Brigitte C. M., additional, Haringhuizen, Annebeth W., additional, Hoekstra, Ronald, additional, Hunting, J. Cornelis B., additional, Kerver, Emile D., additional, Mathijssen-van Stein, Danielle, additional, Polée, Marco B., additional, Pruijt, Johannes F. M., additional, Quarles van Ufford-Mannesse, Patricia, additional, Radema, Sandra, additional, Rietbroek, Ronald C., additional, Simkens, Lieke H. J., additional, Tanis, Bea C., additional, ten Bokkel Huinink, Daan, additional, Tjin-A-Ton, Manuel L. R., additional, Tromp-van Driel, Cathrien S., additional, Troost, Monique M., additional, van de Wouw, Agnes J., additional, van den Berkmortel, Franchette W. P. J., additional, van der Pas, Anke J. M., additional, van der Velden, Ankie M. T., additional, van Dijk, Marjan A., additional, van Dodewaard-de Jong, Joyce M., additional, van Druten, Edith B., additional, van Voorthuizen, Theo, additional, Jan Veldhuis, Gerrit, additional, Verheul, Henk M. W., additional, Vestjens, Hanneke J. H. M. J., additional, Vincent, Jeroen, additional, Kranenburg, Onno W., additional, Punt, Cornelis J. A., additional, Vink, Geraldine R., additional, Roodhart, Jeanine M. L., additional, and Koopman, Miriam, additional

Published
2020
Full Text
View/download PDF

8. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A., primary, Peeters, Petra H. M., additional, Dorresteijn, Bram, additional, de Jong, Pim A., additional, Jourdan, Marion, additional, Creemers, Geert‐Jan M., additional, Erdkamp, Frans L. G., additional, de Jongh, Felix E., additional, Kint, Peter A. M., additional, Poppema, Boelo J., additional, Radema, Sandra A., additional, Simkens, Lieke H. J., additional, Tanis, Bea C., additional, Tjin‐A‐Ton, Manuel L. R., additional, Van Der Velden, Ankie, additional, Punt, Cornelis J. A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2019
Full Text
View/download PDF

9. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.

Author

Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, and May, Anne M.

Subjects
SKELETAL muscle, COLORECTAL cancer, METASTASIS, SECONDARY analysis, BODY mass index
Abstract

Background: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. Methods: This is a retrospective analysis of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine + bevacizumab (CAP‐B) or observation, after six cycles capecitabine + oxaliplatin + bevacizumab (CAPOX‐B). Upon first disease progression (PD1), CAPOX‐B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time‐periods; p1: during initial CAPOX‐B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1‐p3, with PD1, PD2, and survival was studied by Cox regression models. Results: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean −0.6 SMI units [95% CI −1.07;‐0.26] and p3: −2.2 units [−2.7;‐1.8], whereas during p2, SMI increased + 1.2 units [0.8‐1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09‐1.35]; 1.54 [1.31‐1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10‐1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14‐1.63]). Conclusions: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

11. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer.

Author

Smit KC, Derksen JWG, Beets GLO, Belt EJT, Berbée M, Coene PPLO, van Cruijsen H, Davidis MA, Dekker JWT, van Dodewaard-de Jong JM, Haringhuizen AW, Helgason HH, Hendriks MP, Hoekstra R, de Hingh IHJT, IJzermans JNM, Janssen JJB, Konsten JLM, Los M, Mekenkamp LJM, Nieboer P, Peeters KCMJ, Peters NAJB, Pruijt HJFM, Quarles van Ufford-Mannesse P, Rietbroek RC, Schiphorst AHW, Schouten van der Velden A, Schrauwen RWM, Sie MPS, Sommeijer DW, Sonneveld DJA, Stockmann HBAC, Tent M, Terheggen F, Tjin-A-Ton MLR, Valkenburg-van Iersel L, van der Velden AMT, Vles WJ, van Voorthuizen T, Wegdam JA, de Wilt JHW, Koopman M, May AM, and On Behalf Of The Plcrc Study Group

Abstract

Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We therefore conducted a study in mCRC patients participating in the Prospective Dutch Colorectal Cancer cohort. PA was assessed with the validated SQUASH questionnaire, filled-in within a maximum of 60 days after diagnosis of mCRC. PA was quantified by calculating Metabolic Equivalent Task (MET) hours per week. American College of Sports and Medicine (ACSM) PA guideline adherence, tertiles of moderate to vigorous PA (MVPA), and sport and leisure time MVPA (MVPA-SL) were assessed as well. Vital status was obtained from the municipal population registry. Cox proportional-hazards models were used to study the association between PA determinants and all-cause mortality adjusted for prognostic patient and treatment-related factors. In total, 293 mCRC patients (mean age 62.9 ± 10.6 years, 67% male) were included in the analysis. Compared to low levels, moderate and high levels of MET-hours were significantly associated with longer OS (fully adjusted hazard ratios: 0.491, (95% CI 0.299-0.807, p value = 0.005) and 0.485 (95% CI 0.303-0.778, p value = 0.003), respectively), as were high levels of MVPA (0.476 (95% CI 0.278-0.816, p value = 0.007)) and MVPA-SL (0.389 (95% CI 0.224-0.677, p value < 0.001)), and adherence to ACSM PA guidelines compared to non-adherence (0.629 (95% CI 0.412-0.961, p value = 0.032)). The present study provides evidence that higher PA levels at diagnosis of mCRC are associated with longer OS.

Published
2022
Full Text
View/download PDF

12. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Author

Wensink GE, Elferink MAG, May AM, Mol L, Hamers PAH, Bakker SD, Creemers GJ, de Groot JWB, de Klerk GJ, Haberkorn BCM, Haringhuizen AW, Hoekstra R, Hunting JCB, Kerver ED, Mathijssen-van Stein D, Polée MB, Pruijt JFM, Quarles van Ufford-Mannesse P, Radema S, Rietbroek RC, Simkens LHJ, Tanis BC, Ten Bokkel Huinink D, Tjin-A-Ton MLR, Tromp-van Driel CS, Troost MM, van de Wouw AJ, van den Berkmortel FWPJ, van der Pas AJM, van der Velden AMT, van Dijk MA, van Dodewaard-de Jong JM, van Druten EB, van Voorthuizen T, Jan Veldhuis G, Verheul HMW, Vestjens HJHMJ, Vincent J, Kranenburg OW, Punt CJA, Vink GR, Roodhart JML, and Koopman M

Subjects
Adult, Aged, Colorectal Neoplasms mortality, DNA Mismatch Repair, Female, Humans, Male, Middle Aged, Survival Analysis, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Microsatellite Instability
Abstract

Background: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy., Methods: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified., Results: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients., Conclusion: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results